Nathanael Gay, MD
Hematology & Oncology · Spokane, WANPI 1417214420
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $854 of the $1,136 with a category attached, or 75.2%. It is spread thinly across 24 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $429, 3.2 times the $134 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.
Across 44 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$120
- Bristol Myers Squibb$106
- Pfizer$106
- Genentech USA, Inc.$84
- AstraZeneca$66
- E.r. Squibb & Sons, L.L.C.$62
- plus $592 from 18 others
Across 5 payments — averaging $36,031 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$177K
- Merck$3K
What the payments were for
- Food & beverage$85475%
- Education$28225%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $120 |
| Bristol Myers Squibb | 5 | $106 |
| Pfizer | 5 | $106 |
| Genentech USA, Inc. | 1 | $84 |
| AstraZeneca | 2 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Mirati Therapeutics, Inc. | 2 | $59 |
| Genentech, Inc. | 1 | $53 |
| Novartis | 3 | $50 |
| Amgen | 3 | $50 |
| AbbVie | 2 | $48 |
| Sanofi | 2 | $44 |
| Astellas Pharma US Inc | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Gilead | 2 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $29 |
| Merck | 1 | $26 |
| Array Biopharma Inc | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| AVEO Pharmaceuticals, Inc. | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Adaptive Biotechnologies Corporation | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $14 |
How this compares
$1,136 in reported general payments places this provider in the 50th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 37 | $624,605 |
| PomalystPomalidomide | 29 | $617,050 |
| VerzenioAbemaciclib | 33 | $499,242 |
| KisqaliRibociclib Succinate | 29 | $444,016 |
| CalquenceAcalabrutinib Maleate | 28 | $429,344 |
| AlecensaAlectinib Hcl | 25 | $407,954 |
| TagrissoOsimertinib Mesylate | 23 | $376,329 |
| ErleadaApalutamide | 25 | $366,995 |
| IbrancePalbociclib | 22 | $336,708 |
| RevlimidLenalidomide | 19 | $331,414 |
| BrukinsaZanubrutinib | 26 | $312,432 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 28 | $283,236 |
| KeytrudaPembrolizumab | 22 | $256,251 |
| NubeqaDarolutamide | 17 | $217,118 |
| RydaptMidostaurin | 11 | $214,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $66 | $805,67451 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $62 | $729,86841 claims |
| NovartisKisqali, Rydapt | $50 | $658,73240 claims |
| Incyte CorporationJakafi | $21 | $624,60537 claims |
| Johnson & JohnsonErleada, Xarelto | $120 | $429,67690 claims |
| Genentech USA, Inc.Alecensa | $84 | $407,95425 claims |
| PfizerIbrance, Eliquis, Retacrit | $106 | $403,01898 claims |
| Bristol Myers SquibbRevlimid | $106 | $331,41419 claims |
| MerckKeytruda | $26 | $256,25122 claims |
| AbbVieVenclexta | $48 | $164,80711 claims |
| AmgenXgeva | $50 | $65,53021 claims |
| Genentech, Inc.Pegasys | $53 | $55,44513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Spokane
- Thomas BoydSpokane$187K
- William DittmanSpokane$150K
- Arvind ChaudhrySpokane$71K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.